L3VLUP
ProSign in

STVN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

STVNLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • STVN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterSTVNLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 20212 holders, $23m31 holders, $29.9bn
Q4 20214 holders, $15m31 holders, $34.7bn
Q1 20223 holders, $13m24 holders, $35.3bn
Q2 20221 holders, $791k33 holders, $42.7bn
Q3 20221 holders, $847k31 holders, $43.4bn
Q4 20221 holders, $898k31 holders, $46.6bn
Q1 20232 holders, $47m33 holders, $44.3bn
Q2 20233 holders, $117m37 holders, $59.6bn
Q3 20233 holders, $108m44 holders, $67.6bn
Q4 20233 holders, $115m45 holders, $73.6bn
Q1 20245 holders, $194m41 holders, $95.3bn
Q2 20244 holders, $121m43 holders, $110bn
Q3 20243 holders, $128m45 holders, $107bn
Q4 20243 holders, $153m46 holders, $93.9bn
Q1 20253 holders, $141m42 holders, $98.4bn
Q2 20253 holders, $177m43 holders, $93.2bn
Q3 20253 holders, $193m39 holders, $86.7bn
Q4 20253 holders, $144m41 holders, $123bn
Q1 20264 holders, $96m39 holders, $106bn
Q2 20263 holders, $160m44 holders, $132bn
STVN

Stevanato Group S P A

Holders
3
Reported value
$160m
Buyers
7
Sellers
11

Breadth -4 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
44
Reported value
$132bn
Buyers
24
Sellers
24

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only STVN (1)

First Eagle Investment Management LLC

Only LLY (42)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Discovery Capital Management LLC, Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Glenview Capital Management LLC, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, and 17 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →